436 related articles for article (PubMed ID: 26288846)
1. Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex.
Kolumam G; Chen MZ; Tong R; Zavala-Solorio J; Kates L; van Bruggen N; Ross J; Wyatt SK; Gandham VD; Carano RA; Dunshee DR; Wu AL; Haley B; Anderson K; Warming S; Rairdan XY; Lewin-Koh N; Zhang Y; Gutierrez J; Baruch A; Gelzleichter TR; Stevens D; Rajan S; Bainbridge TW; Vernes JM; Meng YG; Ziai J; Soriano RH; Brauer MJ; Chen Y; Stawicki S; Kim HS; Comps-Agrar L; Luis E; Spiess C; Wu Y; Ernst JA; McGuinness OP; Peterson AS; Sonoda J
EBioMedicine; 2015 Jul; 2(7):730-43. PubMed ID: 26288846
[TBL] [Abstract][Full Text] [Related]
2. FGF21 mimetic antibody stimulates UCP1-independent brown fat thermogenesis via FGFR1/βKlotho complex in non-adipocytes.
Chen MZ; Chang JC; Zavala-Solorio J; Kates L; Thai M; Ogasawara A; Bai X; Flanagan S; Nunez V; Phamluong K; Ziai J; Newman R; Warming S; Kolumam G; Sonoda J
Mol Metab; 2017 Nov; 6(11):1454-1467. PubMed ID: 29107292
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetic characterization of an adipose tissue-targeting monoclonal antibody in obese and non-obese animals.
Rajan S; Mandikian D; Baruch A; Gelzleichter TR; Stevens D; Sonoda J; Cowan K; Boswell CA; Stefanich E
MAbs; 2017; 9(8):1379-1388. PubMed ID: 28895785
[TBL] [Abstract][Full Text] [Related]
4. Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex.
Foltz IN; Hu S; King C; Wu X; Yang C; Wang W; Weiszmann J; Stevens J; Chen JS; Nuanmanee N; Gupte J; Komorowski R; Sekirov L; Hager T; Arora T; Ge H; Baribault H; Wang F; Sheng J; Karow M; Wang M; Luo Y; McKeehan W; Wang Z; Véniant MM; Li Y
Sci Transl Med; 2012 Nov; 4(162):162ra153. PubMed ID: 23197570
[TBL] [Abstract][Full Text] [Related]
5. FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases.
Sonoda J; Chen MZ; Baruch A
Horm Mol Biol Clin Investig; 2017 May; 30(2):. PubMed ID: 28525362
[TBL] [Abstract][Full Text] [Related]
6. FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia.
Lan T; Morgan DA; Rahmouni K; Sonoda J; Fu X; Burgess SC; Holland WL; Kliewer SA; Mangelsdorf DJ
Cell Metab; 2017 Nov; 26(5):709-718.e3. PubMed ID: 28988823
[TBL] [Abstract][Full Text] [Related]
7. Chronic high-sucrose diet increases fibroblast growth factor 21 production and energy expenditure in mice.
Maekawa R; Seino Y; Ogata H; Murase M; Iida A; Hosokawa K; Joo E; Harada N; Tsunekawa S; Hamada Y; Oiso Y; Inagaki N; Hayashi Y; Arima H
J Nutr Biochem; 2017 Nov; 49():71-79. PubMed ID: 28886439
[TBL] [Abstract][Full Text] [Related]
8. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.
Wu X; Ge H; Lemon B; Weiszmann J; Gupte J; Hawkins N; Li X; Tang J; Lindberg R; Li Y
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14379-84. PubMed ID: 19706524
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic Effects of FGF21 Are Independent of the "Browning" of White Adipose Tissue.
Véniant MM; Sivits G; Helmering J; Komorowski R; Lee J; Fan W; Moyer C; Lloyd DJ
Cell Metab; 2015 May; 21(5):731-8. PubMed ID: 25955208
[TBL] [Abstract][Full Text] [Related]
10. FGF21-FGFR1 Coordinates Phospholipid Homeostasis, Lipid Droplet Function, and ER Stress in Obesity.
Ye M; Lu W; Wang X; Wang C; Abbruzzese JL; Liang G; Li X; Luo Y
Endocrinology; 2016 Dec; 157(12):4754-4769. PubMed ID: 27690692
[TBL] [Abstract][Full Text] [Related]
11. FGF21 improves glucose homeostasis in an obese diabetes-prone mouse model independent of body fat changes.
Laeger T; Baumeier C; Wilhelmi I; Würfel J; Kamitz A; Schürmann A
Diabetologia; 2017 Nov; 60(11):2274-2284. PubMed ID: 28770320
[TBL] [Abstract][Full Text] [Related]
12. Antibody-mediated activation of the FGFR1/Klothoβ complex corrects metabolic dysfunction and alters food preference in obese humans.
Baruch A; Wong C; Chinn LW; Vaze A; Sonoda J; Gelzleichter T; Chen S; Lewin-Koh N; Morrow L; Dheerendra S; Boismenu R; Gutierrez J; Wakshull E; Wilson ME; Arora PS
Proc Natl Acad Sci U S A; 2020 Nov; 117(46):28992-29000. PubMed ID: 33139537
[TBL] [Abstract][Full Text] [Related]
13. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y
PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730
[TBL] [Abstract][Full Text] [Related]
14. FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms.
BonDurant LD; Ameka M; Naber MC; Markan KR; Idiga SO; Acevedo MR; Walsh SA; Ornitz DM; Potthoff MJ
Cell Metab; 2017 Apr; 25(4):935-944.e4. PubMed ID: 28380381
[TBL] [Abstract][Full Text] [Related]
15. FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss.
Owen BM; Ding X; Morgan DA; Coate KC; Bookout AL; Rahmouni K; Kliewer SA; Mangelsdorf DJ
Cell Metab; 2014 Oct; 20(4):670-7. PubMed ID: 25130400
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1.
Wu AL; Kolumam G; Stawicki S; Chen Y; Li J; Zavala-Solorio J; Phamluong K; Feng B; Li L; Marsters S; Kates L; van Bruggen N; Leabman M; Wong A; West D; Stern H; Luis E; Kim HS; Yansura D; Peterson AS; Filvaroff E; Wu Y; Sonoda J
Sci Transl Med; 2011 Dec; 3(113):113ra126. PubMed ID: 22174314
[TBL] [Abstract][Full Text] [Related]
17. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.
Hale C; Chen MM; Stanislaus S; Chinookoswong N; Hager T; Wang M; Véniant MM; Xu J
Endocrinology; 2012 Jan; 153(1):69-80. PubMed ID: 22067317
[TBL] [Abstract][Full Text] [Related]
18. Myricetin-induced brown adipose tissue activation prevents obesity and insulin resistance in db/db mice.
Hu T; Yuan X; Wei G; Luo H; Lee HJ; Jin W
Eur J Nutr; 2018 Feb; 57(1):391-403. PubMed ID: 28439667
[TBL] [Abstract][Full Text] [Related]
19. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue.
Adams AC; Yang C; Coskun T; Cheng CC; Gimeno RE; Luo Y; Kharitonenkov A
Mol Metab; 2012; 2(1):31-7. PubMed ID: 24024127
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice.
Bajzer M; Olivieri M; Haas MK; Pfluger PT; Magrisso IJ; Foster MT; Tschöp MH; Krawczewski-Carhuatanta KA; Cota D; Obici S
Diabetologia; 2011 Dec; 54(12):3121-31. PubMed ID: 21987346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
